Features of treatment of type 2 diabetes mellitus in patients with concomitant pathology
https://doi.org/10.18705/1607-419X-2009-15-1-31-41
Abstract
Cardiovascular morbidity is widely spread in patients with type 2 diabetes mellitus. Cardiovascular mortality risk in patients with type 2 diabetes mellitus is twice to six times as high as in patients without diabetes. The incidence of macrovascular complications, such as strokes and peripheral arterial disease is very high, and the cardiovascular events associated with type 2 diabetes are the major cause of mortality in these patients. This article reviews the efficacy and safety of various antidiabetic drugs in patients with concomitant diseases, and regards diabetes management in elderly population. The available evidence on treatment of elder adults with type 2 diabetes and concomitant diseases is discussed, and a general approach to therapy is suggested.
About the Authors
E. V. Shlyakhto
Federal Almazov Heart, Blood and Endocrinology Centre
Russian Federation
Russian Federation
E. N. Grineva
Federal Almazov Heart, Blood and Endocrinology Centre
Russian Federation
Russian Federation
A. Yu. Babenko
Federal Almazov Heart, Blood and Endocrinology Centre
Russian Federation
Russian Federation
A. V. Dronova
Federal Almazov Heart, Blood and Endocrinology Centre
Russian Federation
Russian Federation
References
1. DeFronzo RA. Pharmacologic therapy for type 2 diabetes mellitus. Ann Intern Med. 1999;131:281-303.
2.
3. Diabetes Control and Complications Trial Research Group: The effect of intensive treatment of diabetes on the development and progression of longterm complications in insulindependent diabetes mellitus. N Eng J Med. 1999;329:977-986.
4.
5. Eschwege E. The dysmetabolic syndrome, insulin resistance and increased cardiovascular morbidity and mortality in type 2 diabetes: etiological factors in the development of CV complications. Diabetes Metab. 2003;29:6S19-6S27.
6.
7. Аметов А.С. Инсулиносекреция и инсулинорезистентность: две стороны одной медали. Проблемы эндокринологии. 2002;48(3):31-36.
8.
9. Bloomgarden ZT. Developments in diabetes and insulin resistance. Diabetes Care. 2006;29:161-7.
10.
11. McCance DR, Hanson RL, Pettitt DJ, Bennett PH, Hadden DR, Knowler WC. Diagnosing diabetes mellitus: do we need new criteria? Diabetologia. 1997;40:247-55.
12.
13. Andersson DKG, Lundblad E, Svardsudd K. A model for early diagnosis of type 2 diabetes mellitus in primary health care. Diabet Med. 1993;10:167-73.
14.
15. Odegard PS, Setter SM, Neumiller JJ. Considerations for the Pharmacological Treatment of Diabetes in Older Adults. Diabetes Spectrum. 2007;20:239-47
16.
17. Nathan DM, Buse JB, Davidson MB, Heine RJ, Holman RR, Sherwin R, Zinman B. Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. Diabetes Care. 2006;29:1963-72.
18.
19. Abbasi F, Chu JW, McLaughlin T, Lamendola C, Leary ET, Reaven GM. Effect of metformin treatment on multiple cardiovascular disease risk factors in patients with type 2 diabetes mellitus. Metabolism. 2004;53(2):159-164.
20.
21. Standards of Medical Care in Diabetes-2007. Position Statement. Diabetes Care. 2007;30:S4-S41.
22.
23. Cusi K, De Fronzo RA. Metformin: a review of its metabolic effect. Diabetes Rev. 1998;6:89-131.
24.
25. Bailey C, Campbell W. Metformin - The Gold Standrd. A Scientific Handbook; 2007
26.
27. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ. 1998;317:703-13.
28.
29. Sakharova OV, Inzucchi SE. Treatment of diabetes in the elderly. Addressing its complexities in this high-risk group.: Postgrad Med. 2005 Nov;118(5):19-26, 29.
30.
31. Бабичев В.Н., Савельева М.П., Балаболкин М.И. Характеристика рецепторов b-клеток поджелудочной железы, связывающих сульфонилмочевинные препараты. Проблемы Эндокринол. 1994;6:47-50.
32.
33. Александров А.А., Бондаренко И.З., Кухаренко С.С. и др. Сахароснижающие сульфаниламиды и «ишемический порог» сердца у больных сахарным диабетом типа 2 с коронарной болезнью сердца. Сахарный диабет. 2002;17(4):18-22.
34.
35. Muller G. The molecular mechanism of insulin-mimetic/sensitizing activity of antidiabetic sulfonylurea drug amaryl. Mol Med. 2000;6:907-33.
36.
37. Peterson MR, Bacon T. A comparison of select cardiovascular outcomes by anti-diabetic prescription drug classes used to treat type 2 diabetes among military health system beneficiaries, fiscal year 2003-2006. Joint meeting of the Endocrinologic and metabolic drugs advisory committee and the Drug safety and risk management advisory committee; 2007
38.
39. Shorr RI, Ray WA, Daugherty JR, Griffin MR. Individual sulfonylureas and serious hypoglycemia in older people. J Am Geriatr Soc. 1996;44:751-55.
40.
41. Brodows RG. Benefits and risks with glyburide and glipizide in elderly NIDDM patients. Diabetes Care. 1992;15:75-80.
42.
43. U.K. Prospective Diabetes Study Group: Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes. Lancet. 1998;352:837-53.
44.
45. Omnicare, Inc.: Geriatric Pharmaceutical Care Guidelines: Diabetes Mellitus. 2007 ed. Covington, Ky., Omnicare, Inc.; 2007:231-51.
46.
47. Del Prato S, Heine RJ, Keilson L, Guitard C, Shen SG, Emmons RP. Treatment of patients over 64 years of age with type 2 diabetes. Diabetes Care. 2003;26:2075-80
48.
49. Choudhury S, Hirschberg Y, Filipek R, Lasseter K, McLeod JF: Single-dose pharmacokinetics of nateglinide in subjects with hepatic cirrhosis. J Clin Pharmcol 2000;40:634-40.
50.
51. Chiasson JL, Josse RG, Gomis R, et al. Acarbose for prevention of type 2 diabetes mellitus. Lancet. 2002;359:2072-77.
52.
53. Hannele Yki-Järvinen. Thiazolidinedinones. N Engl J Med. 2004;351:1106-18.
54.
55. Durbin RJ. Thiazolidinedinone therapy in the prevention/delay of type 2 diabetes in patients with impaired glucose tolerance and insulin resistance. Diabetes Obes Metab. 2004;6:280-5.
56.
57. Nesto RW, Bell D, Bonow RO, Fonseca V, Grundy SM, Horton ES, et al. Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. Circulation 2003;108:2941-48
58.
59. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med. 2007;356:2457-71.
60.
61. Khan MA, St Peter JV, Xue JL. A prospective, randomized comparison of the metabolic effects of pioglitazone or rosiglitazone in patients with type 2 diabetes who were previously treated with troglitazone. Diabetes Care. 2002;25:708-11.
62.
63. Viberti G, Kahn SE, Greene DA, Herman WH, Zinman B, Holman RR, et al. A Diabetes Outcome Progression Trial (ADOPT): an international multicenter study of the comparative efficacy of rosiglitazone, glyburide, and metformin in recently diagnosed type 2 diabetes. Diabetes Care. 2002;25:1737-43.
64.
65. Nielsen LL. Incretin mimetics and DPP-IV ingibitors for the treatment of type 2 diabetes. Drug Discov Today. 2005;10:703-10.
66.
67. Byetta prescribing information. San Diego, Calif. Amylin Pharmaceuticals, Inc.; 2005.
68.
69. Linnebjerg H, Kothare PA, Park S, Mace K, Reddy S, Mitchell M, et al. Effect of renal impairment on the pharmacokinetics of exenatide [article online]. J Clin Pharmacol. 2007.
70.
71. Deacon CF. Dipeptidyl peptidase 4 inhibition with sitagliptin: a new therapy for type 2 diabetes. Expert Opin Invest Drugs. 2007;16:533-45
72.
73. Herman GA, Bergman A, Yi B, Kipnes M. The Sitagliptin Study 012 Group.Tolerability and pharmacokinetics of metformin and the dipeptidyl peptidase-4 inhibitor sitagliptin when co-administered in patients with type 2 diabetes. Curr Med Res Opin. 2006 Oct;22(10):1939-47
74.
75. Kleppinger EL, Vivian EM. Pramlintide for the treatment of diabetes mellitus. Ann Pharmacother 2003;37:1082-9.
76.
77. Hollander PA, Levy P, Fineman MS, Maggs DG, Shen LZ, Strobel SA, et al. Pramlintide as an adjunct to insulin therapy improves long-term glycemic and weight control in patients with type 2 diabetes. Diabetes Care 2003;26:784-90.
78.
79. Janka HU, Plewe G, Busch K. Combination of oral antidiabetic agents with basal insulin versus premixed insulin alone in randomized elderly patients with type 2 diabetes mellitus. J Am Geriatr Soc 2007;55:182-8.
80.
81. Yki-Jarvinen H, Dressler A, Ziemen M. Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes. Diabetes Care. 2000;23:1130-6.
82.
83. Riddle MC, Rosenstock J, Gerich J. The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care. 2003;26:3080-6
84.
85. Holman RR, Thorne KI, Farmer AJ, Davies MJ, Keenan JF, Paul S, et al. Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes. N Engl J Med. 2007;357:1716-30.
86.
87. Zarowitz BJ, Tangalos EG, Hollenack K, O'Shea T. The application of evidence-based principles of care in older persons (issue 3): management of diabetes mellitus. J Am Med Dir Assoc 2006;7:234-40.
88.
89. Esposito K, Ciotola M, Maiorino MI, Gualdiero R, Schisano B, Ceriello A, et al. Addition of Neutral Protamine Lispro Insulin or Insulin Glargine to Oral Type 2 Diabetes Regimens for Patients with Suboptimal Glycemic Control: A Randomized Trial. Ann Intern Med. 2008;149:531-9.
90.
91. Dagdelen S, Ilag LL, Martin S, Jacober SJ, Holman RR, Farmer AJ, et al. Addition of insulin to oral therapy in type 2 diabetes.. NEJM. 2008;358:1197-8.
92.
93. Riddle MC. Starting and Advancing Insulin for Type 2 Diabetes: Algorithms and Individualized Methods Are Both Necessary. J Clin Endocrinol Metab. 2008;93:372-4.
94.
95. Porcellati F, Rossetti P, Ricci Busciantella N, et al. Comparison of pharmacokinetics and dynamics of the long-acting insulin analogs glargine and detemir at steady state in type 1 diabetes mellitus: a double-blind, randomized, cross-over study. Diabetes Care (in press).
96.
97. Pfizer, Inc.: Exubera product information; 2007.
98.
99. Nathan DM, Buse JB, Davidson MB, Ferrannini E, Holman RR, Sherwin R, et al. Medical Management of Hyperglicemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy. Diabetes Care. 2008;31(1):173-5.
100.
Review
For citations:
Shlyakhto E.V., Grineva E.N., Babenko A.Yu., Dronova A.V. Features of treatment of type 2 diabetes mellitus in patients with concomitant pathology. "Arterial’naya Gipertenziya" ("Arterial Hypertension"). 2009;15(1):31-41. (In Russ.) https://doi.org/10.18705/1607-419X-2009-15-1-31-41
Views:
1169
Email this article 